Pharmaceuticals, Biotechnology and Life Sciences
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.
— Dr. Torsten Matthias appointed CEO, scientific founder Prof. Dr. Armin Giese joins as CSO —
— SERY technology in-licensed from Max-Planck Innovation GmbH to design next-generation candidate portfolio —
Regeneron Pharmaceuticals and Sanofi got the approval from the FDA for Dupixent for certain combinations to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled.
Sanofi’s MenQuadfi Meningococcal Polysaccharide Tetanus Toxoid Conjugate Vaccine candidate to help prevent meningococcal meningitis will be reviewed for BLA by the FDA, expecting to reach the decision on April 25, 2020.
appointment of Dr. Virginia Pascual as Medical and Scientific advisor.
“We are delighted to welcome Dr Pascual to Neovacs. Her significant contribution to lupus research and practical knowledge of new treatment approaches, and in particular the role of interferon alpha1, will be key to the next stage of Neovacs’ development. This will be of particular importance for the phase 3 clinical trial protocol and for all others pathologies linked to the neutralization of Interferon alpha such as the ongoing Type 1 Diabetes program” said Miguel Sieler, CEO of Neovacs.”
Dr. Virginia Pascual, MD, is the Founding Director of the Gale and Ira Drukier Institute for Children’s Health at Weill Cornell Medicine in New York City. Her research work has been published in many prestigious scientific revues, she has received multiple awards for her discoveries, from the National Institute of Allergy & Infectious Diseases, and in 2017 the “Lupus Insight Prize” for highly promising research into understanding the events leading to lupus flares.
Before joining the Drukier Institute in New York, Dr Pascual served at the Baylor Institute for Immunology Research in Dallas as Director of the Centre for Inflammation and Genomics. She received her medical degree at the Universidad Complutense in Madrid and specialised in pediatric rheumatology at UT Southwestern Medical Center in Dallas, TX.
As of today, the IFNa Kinoid is the only therapeutic vaccine that has brought positive clinical phase IIb results applying the LLDAS score. This has allowed the clinical and scientific community to envisage a clinical improvement in a patient’s condition enabling a significant reduction in corticosteroid treatments.
As a reminder, lupus is a complex disease with multiple symptoms and the LLDAS is a promising clinical score having reached a wide consensus among the medical and scientific community worldwide. LLDAS has very recently been accepted as primary clinical endpoint by the Chinese FDA.
U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) voted to recommend HPV vaccination with GARDASIL
DUBLIN–(BUSINESS WIRE)–The “Fotivda” report has been added to ResearchAndMarkets.com’s offering. Fotivda (tivozanib; AVEO Oncology/EUSA Pharma/Kyowa Hakko Kirin) is an oral…
Faron Pharmaceuticals’s CEO Markku Jalk said it was disappointing to learn about the magnitude of steroid use in the patient population as RAAA is considered as a traumatic condition and to have only limited inflammatory impact on disease development.
Zealand Pharma has dosed the first out of 64 healthy patients, in a Phase 1 clinical test of ZP7570 as a potential first-in-class next generation treatment of short bowel syndrome (SBS).
Contrad Swiss, a pharmaceutical company focused on breakthrough, innovative products that reframe the world of medicine, announces a new partnership with Dr JO Serrentino.